Filing Flows › Black Diamond Therapeutics (BDTX) › Stock forecast & fair value
Black Diamond Therapeutics (BDTX) stock forecast and price target
Black Diamond Therapeutics (BDTX) trades at $1.74. 7 analysts' median price target is $10.00 (+476%), from $8.00 to $14.00.
Black Diamond Therapeutics' latest quarter
Black Diamond Therapeutics, Q1 2025: revenue $70.0M, operating margin 77.9%, net earnings $56.5M, operating cash flow $53.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BDTX stock?
The median of 7 analysts' 12-month targets is $10.00, +476% from $1.74; the range is $8.00 to $14.00. The average rating is strong buy.
Does Black Diamond Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is BDTX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.